An observational study in COPD Asthma and Pulmonary Fibrosis, sponsored by Spircare Ltd.. Status unknown at 1 site in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-01.
Sponsored by Spircare Ltd. · Observational
The purpose of this study is to assess the accuracy of FRC and airway resistance calculate values of Spircare device as compared to the conventional body plethysmograph in healthy adults and patients with obstructive and restrictive pulmonary diseases/disorders.
680 studies on the registry are indexed under Pulmonary Fibrosis; 119 are open to participants now.
This study's planned enrollment of 90 is below the median of 130 across 229 observational studies indexed under Pulmonary Fibrosis.
Browse Pulmonary Fibrosis studies →This is the only study on the registry with Spircare Ltd. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Phase I Health subjects without respiratory system disease.
Phase II Subjects which are referred to a Pulmonary Functional Testing in the Meir pulmonary unit.
Phase II: Chronic pulmonary patients with lung volume disorders:
Exclusion Criteria:
A full Body Plethysmography examination
The FRC and air way resistance values of the body plethysmograph will be compared to the values of the Spircare device
The primary outcome of the FRC and air way resistance of the Spircare device against the plethysmograph will be displayed as scatter plot. A linear regression and the R2 value will be display as well. The associated Bland-Altman plots comparing the FRC and airway resistance of the Spircare device to the plethysmograph with lines that represent width of 0.1 (±1.96\*SD).
Time frame: September 2017
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.